摘要
目的研究埃克替尼靶向治疗对高龄非小细胞肺癌患者营养及免疫功能的影响。方法选择医院2014年6月至2015年6月接诊的高龄非小细胞肺癌患者80例,按随机数字表法均分为两组,各40例。对照组患者接受传统的GP化学治疗(简称化疗)方案,观察组患者在对照组化疗基础上,应用埃克替尼靶向治疗。治疗2个月后,比较两组患者的体重指数(BMI)、白蛋白(ALB)、血红蛋白(Hb)、前白蛋白(PA)4项营养指标和免疫功能的变化,近期疗效控制效果和治疗后的毒副反应。结果治疗后,观察组患者的4项营养指标均明显升高,且均高于对照组(P<0.05);两组患者的CD4+,CD4+/CD8+水平均明显升高(P<0.05),CD8+水平明显降低(P<0.05),且观察组患者的改善程度明显优于对照组(P<0.05);观察组近期疗效控制率为85.00%,明显优于对照组的47.50%(χ2=12.578 6,P=0.000 4);两组患者治疗过程中皮疹、腹泻、腹胀、恶心及转氨酶升高的发生率比较,均无显著性差异(P>0.05)。结论埃克替尼靶向治疗高龄非小细胞肺癌,患者营养状况及免疫功能改善效果良好,且治疗安全性较高,值得临床推广。
Objective To study the effects of icotinib targeted treatment for elderly nutrition and immune function in patients with non- small cell lung cancer. Methods 80 cases of elderly patients with non-small cell lung cancer patients from June 2014 to June 2015 were selected according to the random number table method and divided for two groups,40 cases in each group. The control group was treated with traditional GP chemotherapy, on the basis of the control group, the observation group received icotinib targeted treat- ment. After 2 months of treatment, the four nutrition indexes of BMI, ALB, HB, and PA, as well as changes of immune function and short- term efficacy and adverse reactions in the two groups were analyzed. Results After treatment,the BMI,ALB,Hb,PA were signifi- cantly increased in the two groups and the observation group was significantly higher than those in the control group（ P 〈 0. 05）. The levels of CD4＋, CD4＋/CD8＋ in the two groups were significantly increased（P 〈 0. 05）, CD8＋ decreased significantly（P 〈 0. 05）,and the observation group was obviously better than the control group（P 〈 0. 05）. The control rate in the near future of the observation was 85.00% ,whicg was much better than 47.50% in the control group（X2 =12. 578 6, P=0.000 4）.There was no significant differ- ence in the incidence of skin rash,diarrhea,abdominal distension,nausea and elevated aminotransferase in the two groups（P 〉 0. 05）. Conclusion Icotinib targeted therapy on elderly patients with non- small cell lung cancer is conducive to the nutritional status and immune function and has high safety,which is worthy of clinical promotion.
出处
《中国药业》
CAS
2016年第16期34-37,共4页
China Pharmaceuticals
关键词
非小细胞肺癌
埃克替尼
免疫功能
靶向治疗
non - small cell lung cancer
icotinib
immune function
targeted treatment
